JP6306514B2 - Ｈｉｖワクチン接種のための免疫原 - Google Patents

Ｈｉｖワクチン接種のための免疫原 Download PDF

Info

Publication number
JP6306514B2
JP6306514B2 JP2014553750A JP2014553750A JP6306514B2 JP 6306514 B2 JP6306514 B2 JP 6306514B2 JP 2014553750 A JP2014553750 A JP 2014553750A JP 2014553750 A JP2014553750 A JP 2014553750A JP 6306514 B2 JP6306514 B2 JP 6306514B2
Authority
JP
Japan
Prior art keywords
seq
sequence
amino acid
acid sequence
identity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014553750A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015509707A5 (enExample
JP2015509707A (ja
Inventor
ブランデル、クリスティアン
プハダス、ベアトリス モテ
プハダス、ベアトリス モテ
リャノ、アヌスカ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
IrsiCaixa Institut de Recerca de la Sida
Original Assignee
IrsiCaixa Institut de Recerca de la Sida
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by IrsiCaixa Institut de Recerca de la Sida filed Critical IrsiCaixa Institut de Recerca de la Sida
Publication of JP2015509707A publication Critical patent/JP2015509707A/ja
Publication of JP2015509707A5 publication Critical patent/JP2015509707A5/ja
Application granted granted Critical
Publication of JP6306514B2 publication Critical patent/JP6306514B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2014553750A 2012-01-27 2013-01-28 Ｈｉｖワクチン接種のための免疫原 Active JP6306514B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12382031.8 2012-01-27
EP12382031.8A EP2620446A1 (en) 2012-01-27 2012-01-27 Immunogens for HIV vaccination
PCT/EP2013/051596 WO2013110818A2 (en) 2012-01-27 2013-01-28 Immunogens for hiv vaccination

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018041572A Division JP6749357B2 (ja) 2012-01-27 2018-03-08 Ｈｉｖワクチン接種のための免疫原

Publications (3)

Publication Number Publication Date
JP2015509707A JP2015509707A (ja) 2015-04-02
JP2015509707A5 JP2015509707A5 (enExample) 2016-03-17
JP6306514B2 true JP6306514B2 (ja) 2018-04-04

Family

ID=47603800

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014553750A Active JP6306514B2 (ja) 2012-01-27 2013-01-28 Ｈｉｖワクチン接種のための免疫原
JP2018041572A Active JP6749357B2 (ja) 2012-01-27 2018-03-08 Ｈｉｖワクチン接種のための免疫原

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018041572A Active JP6749357B2 (ja) 2012-01-27 2018-03-08 Ｈｉｖワクチン接種のための免疫原

Country Status (16)

Country Link
US (4) US9988425B2 (enExample)
EP (3) EP2620446A1 (enExample)
JP (2) JP6306514B2 (enExample)
KR (2) KR102140778B1 (enExample)
CN (2) CN104080800B (enExample)
AU (2) AU2013213564B2 (enExample)
BR (1) BR112014018396B1 (enExample)
CA (1) CA2862172C (enExample)
ES (1) ES2932407T3 (enExample)
IL (2) IL233771B (enExample)
IN (1) IN2014DN06164A (enExample)
MX (2) MX358711B (enExample)
NZ (3) NZ734689A (enExample)
RU (2) RU2721274C2 (enExample)
WO (1) WO2013110818A2 (enExample)
ZA (1) ZA201405204B (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9090673B2 (en) * 2003-12-12 2015-07-28 City Of Hope Synthetic conjugate of CpG DNA and T-help/CTL peptide
AU2009333559B2 (en) 2008-12-09 2015-03-12 Gilead Sciences, Inc. Modulators of toll-like receptors
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
CN107635579A (zh) * 2014-03-21 2018-01-26 纽泰克温图斯公司 非天然发生的猪生殖和呼吸综合征病毒(prrsv)和使用方法
TWI733652B (zh) 2014-07-11 2021-07-21 美商基利科學股份有限公司 用於治療ＨＩＶ之ｔｏｌｌ樣受體調節劑
JP2017526730A (ja) 2014-09-16 2017-09-14 ギリアード サイエンシーズ， インコーポレイテッド Ｔｏｌｌ様受容体モジュレーターの固体形態
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
US20220226459A1 (en) * 2019-05-22 2022-07-21 Aelix Therapeutics, S.L. Dosage regimens for vaccines
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
AU2020315598B2 (en) 2019-07-16 2024-12-12 Gilead Sciences, Inc. HIV vaccines and methods of making and using
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines
WO2021228816A1 (en) 2020-05-12 2021-11-18 Janssen Vaccines & Prevention B.V. Administration of homologous adenoviral vectors
US20220118081A1 (en) 2020-10-20 2022-04-21 Janssen Vaccines & Prevention B.V. HIV vaccine regimens
EP4277652A1 (en) 2021-01-14 2023-11-22 Gilead Sciences, Inc. Hiv vaccines and methods of using
WO2024084441A1 (en) 2022-10-19 2024-04-25 Aelix Therapeutics, S.L. Combination hiv vaccine
EP4417974A1 (en) 2023-02-17 2024-08-21 Fundació Privada Institut de Recerca de la SIDA-Caixa Cd33 as a biomarker of hiv control
WO2025017540A1 (en) 2023-07-20 2025-01-23 Aelix Therapeutics, S.L. Method of treatment of hiv infection with vaccine
CN118389553A (zh) * 2024-03-01 2024-07-26 中国科学技术大学 免疫增效rna分子及其组合物、疫苗与试剂盒

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE787901A (fr) 1971-09-11 1972-12-18 Freistaat Bayern Represente Pa Vaccin antivariolique
US6610476B1 (en) 1984-08-22 2003-08-26 The United States Of America As Represented By The Department Of Health And Human Services Detection of HIV-1 DNA
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US6294322B1 (en) 1988-01-26 2001-09-25 The United States Of America As Represented By The Department Of Health And Human Services Multideterminant peptides that elicit helper T-lymphocyte cytotoxic T-lymphocyte and neutralizing antibody responses against HIV-1
US5976541A (en) 1988-01-26 1999-11-02 The United States Of America As Represented By The Department Of Health And Human Services Potent peptide for stimulation of cytotoxic T lymphocytes specific for the HIV-1 envelope
US5081226A (en) 1986-12-30 1992-01-14 The United States Of America As Represented By The Department Of Health And Human Services Synthetic peptides sharing sequence homology with the HIV envelope protein
US6210873B1 (en) 1987-08-28 2001-04-03 Board Of Regents, The University Of Texas System Methods and compositions for the priming of specific cytotoxic T-lymphocyte response
US5128319A (en) 1987-08-28 1992-07-07 Board Of Regents, The University Of Texas System Prophylaxis and therapy of acquired immunodeficiency syndrome
GB8918200D0 (en) 1989-08-09 1989-09-20 Medical Res Council The peptide fragments of hiv
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US7319000B1 (en) 1992-09-16 2008-01-15 Board Of Regents, The University Of Texas System Compositions and methods for eliciting immune or anti-infective responses
JPH08511007A (ja) 1993-06-09 1996-11-19 コノート ラボラトリーズ リミテッド タンデム合成ｈｉｖ−１ペプチド
WO1996020013A1 (en) 1994-12-24 1996-07-04 Cambridge University Technical Services Limited Improvements in or relating to endometrial function
UA68327C2 (en) 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
US6093400A (en) 1996-08-09 2000-07-25 Cel Sci Corporation Modified HGP-30 peptides, conjugates, compositions and methods of use
AU731367B2 (en) 1996-08-09 2001-03-29 Viral Technologies, Inc. HIV p-17 peptide fragment, compositions containing and methods for producing and using same
US6031647A (en) 1996-10-23 2000-02-29 Nortel Networks Corporation Stable power control for optical transmission systems
US5972339A (en) 1997-11-13 1999-10-26 The General Hospital Corporation Method of eliciting anti-HIV-1 helper T cell responses
US20040106136A1 (en) 1999-01-25 2004-06-03 Musc Foundation For Research Development Method for testing drug susceptibility of HIV
CN1297932A (zh) * 1999-11-30 2001-06-06 上海博容基因开发有限公司 一种新的多肽——人脂蛋白前体蛋白信号肽11和编码这种多肽的多核苷酸
WO2001047955A2 (en) * 1999-12-23 2001-07-05 Medical Research Council Improvements in or relating to immune responses to hiv
FR2803307A1 (fr) 1999-12-30 2001-07-06 Centre Nat Rech Scient Lignees de lymphocytes t cd4 specifiques de type th1 et procede pour leur induction ex vivo
US20040105871A1 (en) 2000-03-02 2004-06-03 Robinson Harriet L. Compositions and methods for generating an immune response
CN1312275A (zh) * 2000-03-07 2001-09-12 上海博德基因开发有限公司 一种新的多肽——人热休克蛋白15和编码这种多肽的多核苷酸
JP2003531865A (ja) 2000-04-28 2003-10-28 アメリカ合衆国 Ｄｎａおよびワクシニアウイルスベクターワクチンの組み合わせを用いた免疫原性の改善
EP1156112B1 (en) 2000-05-18 2006-03-01 Geneart GmbH Synthetic gagpol genes and their uses
AUPQ776100A0 (en) 2000-05-26 2000-06-15 Australian National University, The Synthetic molecules and uses therefor
CA2419822C (en) 2000-08-14 2011-02-08 Gary J. Nabel Modifications of hiv env, gag, and pol enhance immunogenicity for genetic immunization
CN101676389A (zh) 2000-11-23 2010-03-24 巴法里安诺迪克有限公司 改良安卡拉痘苗病毒变体
CU23235A1 (es) 2001-02-28 2007-09-26 Ct Ingenieria Genetica Biotech POXVIRUS RECOMBINANTES PARA PROTEINAS QUIMéRICAS DEL VIRUS DE LA INMUNODEFICIENCIA HUMANA Y SU APLICACION EN LA TERAPéUTICA Y LA PREVENCION DEL SIDA
MXPA04002631A (es) 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
JP2005533752A (ja) 2002-03-19 2005-11-10 パウダーメド リミテッド Ｈｉｖｄｎａワクチン接種におけるアジュバントとしてのイミダゾキノリンアミン
RU2238946C2 (ru) * 2002-04-22 2004-10-27 Государственный научный центр вирусологии и биотехнологии "Вектор" Искусственный белок-иммуноген tci, содержащий множественные ctl-эпитопы основных антигенов вич-1, искусственный ген tci, кодирующий полиэпитопный белок-иммуноген tci
PL218318B1 (pl) 2002-05-16 2014-11-28 Bavarian Nordic As Rekombinowany wirus krowianki Ankara (MVA), zawierająca go komórka, szczepionka lub kompozycja farmaceutyczna, sposób lub zestaw do jego otrzymywania, sekwencja DNA zawierająca genom tego wirusa oraz sposób wykrywania tego wirusa lub komórek nim zainfekowanych
KR20100063126A (ko) 2002-05-16 2010-06-10 버베리안 노딕 에이/에스 Ｈｉｖ 조절/부속 단백질의 융합 단백질
US7501127B2 (en) 2002-05-16 2009-03-10 Bavarian Nordic A/S Intergenic regions as novel sites for insertion of HIV DNA sequences in the genome of Modified Vaccinia virus Ankara
AU2003245729A1 (en) 2002-06-27 2004-01-19 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating a cytotoxic t lymphocyte immune response
US20070248584A1 (en) 2003-06-10 2007-10-25 The University Of Melbourne Immunomodulating Compositions, Uses Therefore and Processes for Their Production
BRPI0414443A (pt) 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
WO2005028634A2 (en) 2003-09-18 2005-03-31 Emory University Improved mva vaccines
WO2005030964A1 (en) * 2003-09-24 2005-04-07 Oxxon Therapeutics Limited Hiv pharmaccines
GB0323840D0 (en) 2003-10-10 2003-11-12 Ist Superiore Sanita Vaccines
WO2005047483A2 (en) 2003-11-12 2005-05-26 Medical Research Council Renta: an hiv immunogen and uses thereof
US20090169503A1 (en) * 2004-07-09 2009-07-02 The Government Of The United States, As Represented By The Secretary Of Dept Of H&Hs Dna-based vaccination of retroviral-infected individuals undergoing treatment
GB0417494D0 (en) 2004-08-05 2004-09-08 Glaxosmithkline Biolog Sa Vaccine
ES2539010T3 (es) 2004-08-27 2015-06-25 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Virus MVA recombinantes que expresan genes env, gag y pol modificados de VIH clado A/G, clado B, y clado C
US8000900B2 (en) 2004-09-21 2011-08-16 Microsoft Corporation Association-based predictions of pathogen characteristics
US20060095241A1 (en) 2004-10-29 2006-05-04 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US8478535B2 (en) 2004-10-29 2013-07-02 Microsoft Corporation Systems and methods that utilize machine learning algorithms to facilitate assembly of aids vaccine cocktails
US20060160070A1 (en) 2004-10-29 2006-07-20 Microsoft Corporation Association-based epitome design
CA2597511A1 (en) 2005-02-24 2006-11-23 Medical Research Council Hivcon: an hiv immunogen and uses thereof
US20100034840A1 (en) * 2005-07-11 2010-02-11 David Apelian Compositions and methods for eliciting an immune response to escape mutants of targeted therapies
BRPI0504117A (pt) 2005-09-05 2007-05-22 Fundacao De Amparo A Pesquisa epìtopos, combinação de epìtopos, usos de epìtopos ou sua combinação, composição, usos da composição, vacinas profiláticas anti-hiv-1, vacinas terapêuticas, método para a identificação de epìtopos e métodos para o tratamento ou prevenção
PL2392587T3 (pl) 2006-03-10 2016-08-31 Peptcell Ltd Sekwencje i kompozycje peptydów
GB0608368D0 (en) 2006-04-28 2006-06-07 Isis Innovation Process for making Oligopeptides
EP2023954B1 (en) 2006-05-19 2013-07-17 Sanofi Pasteur, Inc. Immunological composition
WO2008142479A2 (en) 2006-08-25 2008-11-27 The Government Of The United States Of Amercia, As Represented By The Secretary, Department Of Health And Human Services Intergenic sites between conserved genes in the genome of modified vaccinia ankara (mva) vaccinia virus
US8198082B2 (en) 2007-03-28 2012-06-12 Hiroshima University Method of determining chicken embryonic stem cells
EP2147121B1 (en) * 2007-04-26 2014-12-17 Merck Sharp & Dohme Corp. Synthetic expression vectors for insect cells
WO2009009743A2 (en) * 2007-07-12 2009-01-15 Institute For Advance Study Sequence optimization for expression of a foreign gene
WO2009089568A1 (en) 2008-01-16 2009-07-23 Opal Therapeutics Pty Ltd Immunomodulating compositions and uses therefor
KR20110036618A (ko) 2008-07-16 2011-04-07 베일러 리서치 인스티튜트 극대화된 Ｇａｇ 및 Ｎｅｆ를 수지상 세포에 표적화시킴을 기본으로 하는 ＨＩＶ 백신
US8198062B2 (en) 2008-08-29 2012-06-12 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
US8709775B2 (en) 2008-08-29 2014-04-29 Dsm Ip Assets B.V. Hydrolases, nucleic acids encoding them and methods for making and using them
EP2161279A1 (en) 2008-08-29 2010-03-10 Centre National de la Recherche Scientifique Synthetic peptides corresponding to overlapping neutralizing determinants in the CBD1 epitope induce broadly neutralizing antibodies
WO2010037402A1 (en) * 2008-10-02 2010-04-08 Dako Denmark A/S Molecular vaccines for infectious disease
NZ593598A (en) * 2008-11-18 2013-02-22 Beth Israel Hospital Optimized antiviral vaccines with improved cellular immunogenicity
AU2010295497B2 (en) 2009-09-17 2014-10-09 Global Solutions For Infectious Diseases Immunological compositions for HIV
KR20120093941A (ko) 2009-10-08 2012-08-23 버베리안 노딕 에이/에스 인간에서 ｈｉｖ에 대한 광범위한 ｔ-세포 반응의 생성
AU2010306559B2 (en) 2009-10-16 2015-07-16 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services . Recombinant modified vaccinia Ankara (MVA) vaccinia virus containing restructured insertion sites
WO2011082422A2 (en) 2010-01-04 2011-07-07 The Johns Hopkins University Human immunodeficiency virus (hiv-1) highly conserved and low variant sequences as targets for vaccine and diagnostic applications
CA2817418A1 (en) 2010-11-10 2012-05-18 Laboratorios Del Dr. Esteve, S.A. Highly immunogenic hiv p24 sequences
EP2620446A1 (en) * 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
KR20220011685A (ko) 2019-05-22 2022-01-28 길리애드 사이언시즈, 인코포레이티드 Tlr7 조절 화합물과 hiv 백신의 조합
US20220226459A1 (en) 2019-05-22 2022-07-21 Aelix Therapeutics, S.L. Dosage regimens for vaccines
EP4058058A1 (en) 2019-11-14 2022-09-21 Aelix Therapeutics S.L. Dosage regimens for vaccines

Also Published As

Publication number Publication date
NZ628756A (en) 2016-12-23
US20150050310A1 (en) 2015-02-19
CA2862172A1 (en) 2013-08-01
MX2014009091A (es) 2014-11-10
AU2018203264A1 (en) 2018-05-31
NZ723229A (en) 2019-03-29
CN110372798A (zh) 2019-10-25
HK1204632A1 (en) 2015-11-27
MX358711B (es) 2018-08-31
CA2862172C (en) 2023-07-18
ES2932407T3 (es) 2023-01-18
JP2015509707A (ja) 2015-04-02
US20190055289A1 (en) 2019-02-21
RU2014135053A (ru) 2016-03-27
US20180170971A1 (en) 2018-06-21
IL233771A0 (en) 2014-09-30
WO2013110818A2 (en) 2013-08-01
AU2013213564A1 (en) 2014-09-04
US20210246172A1 (en) 2021-08-12
CN104080800B (zh) 2019-08-27
AU2018203264B2 (en) 2019-07-11
MX2018010483A (es) 2020-09-02
EP2620446A1 (en) 2013-07-31
AU2013213564B2 (en) 2018-03-29
EP2807185A2 (en) 2014-12-03
KR20140122735A (ko) 2014-10-20
JP6749357B2 (ja) 2020-09-02
BR112014018396B1 (pt) 2023-03-21
RU2018104969A (ru) 2019-02-22
IL268629A (en) 2019-10-31
EP2807185B1 (en) 2022-09-14
IL233771B (en) 2019-08-29
KR102108149B1 (ko) 2020-05-12
RU2018104969A3 (enExample) 2019-02-22
BR112014018396A8 (pt) 2017-07-11
BR112014018396A2 (enExample) 2017-06-20
US11919926B2 (en) 2024-03-05
IL268629B (en) 2021-06-30
RU2721274C2 (ru) 2020-05-18
RU2648791C2 (ru) 2018-04-02
NZ734689A (en) 2022-09-30
US10815278B2 (en) 2020-10-27
EP4163290A1 (en) 2023-04-12
KR20190085552A (ko) 2019-07-18
WO2013110818A3 (en) 2013-11-07
US9988425B2 (en) 2018-06-05
US11325946B2 (en) 2022-05-10
CN104080800A (zh) 2014-10-01
KR102140778B1 (ko) 2020-08-06
ZA201405204B (en) 2015-10-28
IN2014DN06164A (enExample) 2015-08-21
JP2018102314A (ja) 2018-07-05

Similar Documents

Publication Publication Date Title
JP6749357B2 (ja) Ｈｉｖワクチン接種のための免疫原
KR101971808B1 (ko) 인간 면역 결핍 바이러스 감염에 대한 방어 면역을 유도하기 위한 방법 및 조성물
EP1240186B1 (en) Improvements in or relating to immune responses to hiv
PL188641B1 (pl) Szczepionka polienv przeciwko HIV, sposób wytwarzania szczepionki polienv,zastosowanie szczepionki polienv,zastosowanie przynajmniej jednego rekombinowanego białka env HIV lub przynajmniej jednego wektora DNA, który koduje ekspresję rekombinowanego białka env HIV, plazmid bifunkcjonalny.
WO2008118936A2 (en) Method of elicting immune response with a modified mva viral hiv-1 vector
HK40016170A (en) Immunogens for hiv vaccination
HK1204632B (en) Immunogens for hiv vaccination

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160127

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160127

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20160826

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161227

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20170327

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20170517

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20171024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180124

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180206

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180308

R150 Certificate of patent or registration of utility model

Ref document number: 6306514

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

S533 Written request for registration of change of name

Free format text: JAPANESE INTERMEDIATE CODE: R313533

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313117